Odonate Therapeutics

Odonate Therapeutics, Inc. is a pharmaceutical company, which engages in the development of therapeutics that improves and extends the lives of patients with cancer. It focuses on the development of tesetaxel, a novel chemotherapy agent that belongs to a class of drugs known as taxanes, which are used in the treatment of cancer. The company was founded in March 2013 and is headquartered in San Diego, CA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Odonate, Inc. is a pharmaceutical company, which engages in the development of therapeutics that improve and extend the lives of patients with cancer. It focuses on the development of tesetaxel, a novel chemotherapy agent that belongs to a class of drugs known as taxanes, which are used in the treatment of cancer. The company was founded in March 2013 and is headquartered in San Diego, CA.

Philadelphia, Pennsylvania--(Newsfile Corp. - May 26, 2022) - Odonate Therapeutics Inc. (NASDAQ: ODT) (OTC: ODTC) has agreed to pay $12.5 million to resolve a proposed securities class action in alleging the pharmaceutical company misled investors about the safety of a new drug for treating cancer. The lawsuit accused the company of making misleading statements and omissions about the development of tesetaxel. The amended complaint alleged that the company and its officers unlawfully inflated the stock...

Grabar Law Office Investigates Potential Claims Against Officers and Directors of Odonate Therapeutics, Inc. After an Agreement to Settle Class Action for $12.5 Million

Philadelphia, Pennsylvania--(Newsfile Corp. - May 10, 2022) - Odonate Therapeutics Inc. (NASDAQ: ODT) (OTC Pink: ODTC) has agreed to pay $12.5 million to resolve a proposed securities class action in alleging the pharmaceutical company misled investors about the safety of a new drug for treating cancer. The lawsuit accused the company of making misleading statements and omissions about the development of tesetaxel. The amended complaint alleged that the company and its officers unlawfully inflated the...

Grabar Law Office Investigates Potential Claims Against Officers and Directors of Odonate Therapeutics, Inc. After an Agreement Is Reached to Settle Class Action

The stock price of Odonate Therapeutics Inc (NASDAQ: ODT) fell by over 17% during intraday trading today. This is why it happened.

Odonate Therapeutics Stock (ODT): Why The Price Plummeted Today

NEW YORK--(BUSINESS WIRE)--Odonate Therapeutics, Inc. (NASDAQ: ODT) today announced that on January 6, 2022 it received written notice from The Nasdaq Stock Market LLC (“Nasdaq”) notifying Odonate that Nasdaq believes that Odonate is a "public shell" pursuant to Listing Rule 5101, and that the continued listing of its securities is no longer warranted. Odonate will not appeal this determination. Therefore, Odonate expects the trading of its common stock on The Nasdaq Stock Market to be suspende

Odonate Announces Expected Delisting of Its Stock

NEW YORK--(BUSINESS WIRE)--Odonate Therapeutics, Inc. (NASDAQ: ODT) today announced that it will commence a share repurchase plan for up to 20 million shares in order to return capital to stockholders. This action is in connection with the Company's previously announced decision to discontinue the development of tesetaxel. Repurchases may be made from time to time at the Company's discretion. The plan has no time limit and can be discontinued at any time. There can be no assurance as to the tim

Odonate Therapeutics Announces Planned Return of Capital to Stockholders through Share Repurchase Plan

NEW YORK--(BUSINESS WIRE)--Odonate Therapeutics, Inc. (NASDAQ: ODT) today announced financial results for the three and nine months ended September 30, 2021. As of September 30, 2021, Odonate had $95.0 million in cash compared to $157.3 million as of December 31, 2020. Odonate's cash used in operating activities for the three and nine months ended September 30, 2021 was $15.1 million and $63.0 million, respectively. Odonate's net loss for the three and nine months ended September 30, 2021 was $

Odonate Therapeutics Announces Financial Results for the Three and Nine Months Ended September 30, 2021

SAN FRANCISCO, Aug. 13, 2021 /PRNewswire/ -- Schubert Jonckheer & Kolbe LLP is investigating potential derivative claims on behalf of shareholders of Odonate Therapeutics, Inc. (NASDAQ: ODT) relating to possible false statements to investors regarding its only product, tesetaxel, a drug the company was formerly developing for the treatment of breast cancer.  A securities class action in the U.S. District Court for the Southern District of California recently survived a motion to dismiss allegations that between December 7, 2017 and March 19, 2021, Odonate and its CEO, CFO, and COO made false and misleading statements about the safety of tesetaxel, which was then undergoing a Phase 3 clinical trial for the treatment of breast cancer.

SHAREHOLDER ALERT: Odonate Therapeutics, Inc. (ODT) Officers and Directors Under Investigation for Possible False Statements to Investors

LOS ANGELES--(BUSINESS WIRE)---- $ODT #investors--The Law Offices of Frank R. Cruz Announces Investigation of Odonate Therapeutics, Inc. (ODT) on Behalf of Investors

The Law Offices of Frank R. Cruz Announces Investigation of Odonate Therapeutics, Inc. (ODT) on Behalf of Investors

NEW YORK--(BUSINESS WIRE)--Odonate Therapeutics, Inc. (NASDAQ: ODT) today announced financial results for the three and six months ended June 30, 2021. In March 2021, Odonate announced the discontinuation of development of tesetaxel and its intent to wind down tesetaxel-related operations. As of June 30, 2021, Odonate has transitioned all patients in tesetaxel studies to appropriate alternative therapies or facilitated continuation of treatment with tesetaxel under compassionate use programs wh

Odonate Therapeutics Announces Financial Results for the Three and Six Months Ended June 30, 2021

Advaxis

ALX Onconology Holdings Inc

Provention Bio Inc

Odonate Therapeutics, Inc. (NASDAQ: ODT), Opthea Limited (NASDAQ: OPT), ALX Oncology Holdings Inc. (NASDAQ: ALXO), Provention Bio, Inc. (NASDAQ: PRVB) and Advaxis, Inc. (NASDAQ: ADXS) are among the biggest biopharma movers Tuesday. Odonate Gains On Institutional Stake: Shares of Odonate, a biopharma which recently announced discontinuation of development of an oral chemotherapy candidate named tesetaxel, are seeing renewed buying following disclosure of institutional stake.

Why Odonate Therapeutics, Opthea, ALX Oncology, Advaxis and Provention Bio Are Moving Today

The stock price of Odonate Therapeutics Inc (NASDAQ: ODT) increased by over 20% pre-market. These are some details you should know.

ODT Stock Price Increases Over 20% Pre-Market: Details

Antares Pharma

GT Biopharma Inc

ObsEva

Ocugen, Inc.

Palatin Technologies

Seelos Therapeutics

Looking for biotech penny stocks to watch right now? Here are 7 for your list this week.

7 Penny Stocks For Your Watch List This Week If You Like Biotech In July

NEW YORK--(BUSINESS WIRE)--Odonate Therapeutics, Inc. (NASDAQ: ODT) today announced financial results for the three months ended March 31, 2021. Odonate recently announced the discontinuation of development of tesetaxel and its intent to wind down tesetaxel-related operations. Odonate is working with clinical sites to transition patients in ongoing tesetaxel studies to appropriate alternative therapies or facilitate continuation of treatment with tesetaxel under compassionate use programs where

Odonate Therapeutics Announces Financial Results for the Three Months Ended March 31, 2021

Odonate Therapeutics (ODT) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock

Odonate Therapeutics (ODT) Enters Oversold Territory

Odonate shut down its Tesetaxel program - and the company itself - without any warning.

Odonate Therapeutics: Lessons Learned

Odonate Therapeutics (ODT) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

Odonate Therapeutics (ODT) is Oversold: Can It Recover?

The stock price of Odonate Therapeutics Inc (NASDAQ: ODT) increased by 12.14% unexpectedly. These are some detail about the company you should know about.

Odonate Therapeutics Stock Price Increased 12.14%: Why It Happened

Investors need to pay close attention to Odonate Therapeutics (ODT) stock based on the movements in the options market lately.

Do Options Traders Know Something About Odonate Therapeutics (ODT) Stock We Don't?

The stock price of Odonate Therapeutics Inc (NASDAQ: ODT) fell by 79.19% yesterday. This is why it happened.

ODT Stock Price Fell 79.19%: Why It Happened

Groupon

Groupon Inc (NASDAQ: GRPN) shares are trading lower Monday after the company announced a proposed private offering of $200 million of convertible senior notes. Groupon acts as the middleman between consumers and merchants, offering a variety of products and services at discounts via its online store.

Why GRPN Stock And ODT Stock Are Trading Lower Today

Shares of Odonate Therapeutics Inc. plummeted 79.0% in active afternoon trading Monday, after the pharmaceutical company said it will wind down operations following disappointing data from its cancer treatment. The company said it determined, following feedback from the Food and Drug Administration in a pre-New Drug Application (pre-NDA) meeting, that tesetaxel, an orally administered chemotherapy agent, is unlikely to receive FDA approval.

Odonate Therapeutics stock plummets toward record low after plan to 'wind down' operations

The company's news was so bad that it's going out of business.

Why Odonate Therapeutics Stock Is Crashing Today

Dyadic International Inc., DE

Marker Therapeutics Inc

Odonate Therapeutics, Inc. (NASDAQ: ODT), Dyadic International, Inc. (NASDAQ: DYAI) and Marker Therapeutics, Inc. (NASDAQ: MRKR) are among the early biotech movers in Monday's session. Odonate to Shut Shop: Odonate, an oncology-focused pharma company, said it is discontinuing the development of tesetaxel following feedback from the Food and Drug Administration in a pre-New Drug Application meeting.

Why Odonate, Marker Therapeutics and Dyadic Are Moving Monday

NEW YORK--(BUSINESS WIRE)--Following feedback from the U.S. Food and Drug Administration (FDA) in a pre-New Drug Application meeting, Odonate Therapeutics, Inc. (NASDAQ: ODT) has concluded that the clinical data package for tesetaxel is unlikely to support FDA approval. Therefore, Odonate is discontinuing the development of tesetaxel and will wind down the operations of the Company. The Company will work with clinical sites to transition patients in ongoing tesetaxel clinical studies to appropr

Odonate Therapeutics Announces Discontinuation of Development of Tesetaxel

NEW YORK--(BUSINESS WIRE)--Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced financial results for the three and twelve months ended December 31, 2020. As of December 31, 2020, Odonate had $157.3 million in cash, compared to $180.5 million as of December 31, 2019. This decrease in cash resulted primarily from cash used in operating activities for

News for Odonate Therapeutics Stock (ODT)